Highlights

  • Recce received ethics approval in August 2026 to add a 208-participant active-controlled arm to its Australian Phase 3 diabetic foot infection trial.
  • An interim analysis for the Australian comparator arm is planned after 104 participants complete the required treatment or follow-up process.
  • FY26 net loss was A$14.96 million, while the company continues to fund late-stage clinical development and pursue a proposed MENA licensing arrangement.

Recce Pharmaceuticals Ltd (ASX:RCE) is moving its lead anti-infective programme into a more comparative phase of clinical testing. In August 2026, a Human Research Ethics Committee approved an amendment adding a randomised, active-controlled, non-inferiority arm to the Australian Phase 3 trial of R327G Topical Gel in diabetic foot infections.

The amended arm will enrol 208 participants and compare R327G with physician-selected antibiotic treatments. An interim analysis is planned after 104 participants have completed the required treatment or follow-up process. The result will be important because it is designed to provide direct comparative clinical evidence rather than relying only on single-arm outcomes.

Company Overview

Recce develops synthetic anti-infective therapies, with R327G as the lead topical programme for diabetic foot infections. The company is running pivotal Phase 3 activity in Australia and Indonesia while also advancing commercial discussions for selected international markets.

Recce Pharmaceuticals Ltd (ASX:RCE) also has a non-binding term sheet with a Middle Eastern pharmaceutical company for a proposed 10-year exclusive licensing arrangement covering R327G in parts of the Middle East and North Africa.

Financial and Operational Position

For FY26, Recce reported a net loss after tax of A$14.96 million. The company remains in a clinical-development phase, so expenditure is directed toward trials, regulatory work, Manufacturing and commercial preparation rather than an established product-sales base.

During 2026, Recce completed an institutional Placement and continued to use research-and-development incentives and financing arrangements to support its clinical programme. Capital availability remains relevant as the Phase 3 trials progress.

What Investors May Watch Next

The nearest clinical markers include the Indonesian Phase 3 interim analysis after 155 participants and the Australian comparator-arm interim analysis after 104 participants. Investors may focus on efficacy, safety and whether the data support regulatory submissions.

Commercially, progress from the non-binding MENA term sheet toward a definitive licence would be another material development. A term sheet does not guarantee a completed transaction, and clinical progress remains the primary driver.

Risks

Clinical trials can Fail to meet efficacy or safety endpoints, and a non-inferiority design requires the treatment to meet a defined comparative threshold. Regulatory review timelines are uncertain, while ongoing clinical development requires capital. The proposed MENA licensing arrangement remains non-binding until definitive agreements are executed.

Key Insights

Recce Pharmaceuticals Ltd (ASX:RCE) has moved its Australian Phase 3 programme toward direct comparison with established antibiotics through a 208-participant active-controlled arm. The next phase is evidence-led: interim clinical data, regulatory progress and the conversion of commercial discussions into binding agreements will determine how the programme develops from here.